Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein-L-isoaspartate O-methyltransferase (PCMT1) is a widely conserved protein repair enzyme that catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to abnormal D-aspartyl and L-isoaspartyl residues. These abnormal residues arise from spontaneous damage, such as deamidation or isomerization, which increases with aging and stress. PCMT1 thus converts these damaged protein sites back to the normal L-aspartate configuration, maintaining protein integrity and protecting cells from dysfunction. This enzyme is highly active in both cytoplasmic and extracellular regions, especially in long-lived and membrane-associated proteins. It plays critical roles in the nervous system—where loss leads to seizures and early death in animal models—and is implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer’s. PCMT1 also modifies histone H4 at aspartate 24, linking its activity to chromatin aging and degradation. Genetic variations in PCMT1 have associations with developmental disorders like spina bifida and reproductive conditions such as premature ovarian failure. While not directly targeted by drugs, PCMT1’s repair activity is essential for cellular viability under oxidative stress and contributes to tissue-specific and systemic protein maintenance[1][2][3][4][5][6].
Methyltransferase activity: Catalyzes the methylation of abnormal D-aspartyl and L-isoaspartyl residues using S-adenosyl-L-methionine (SAM) as the methyl donor, producing S-adenosyl-L-homocysteine and a methyl ester intermediate, which is then hydrolyzed to restore L-aspartate[1][2][4][5][6]. - Repair cycle: Damaged protein residues are converted back to their normal form through cyclic methylation and hydrolysis[6]. - Histone methylation: Methylates aspartate residues in histone H4, affecting chromatin aging and degradation[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein-L-isoaspartate O-methyltransferase (PCMT1).